|Bid||4,300.00 x 6100|
|Ask||4,398.00 x 13000|
|Day's range||4,260.00 - 4,399.00|
|52-week range||3,996.00 - 5,520.00|
|PE ratio (TTM)||16.20|
|Earnings date||27 Jul 2017|
|Dividend & yield||2.80 (4.25%)|
|1y target est||68.85|
These stocks helped pull the market down. Find out why.
AstraZeneca not only failed in a lung cancer trial but its partnership with Dow's Merck appears to be an admission of defeat.
The results from a clinical trial of AstraZeneca's lung cancer treatment increase uncertainty about Bristol-Myers' immuno-oncology franchise, according to BMO analyst Alex Arfaei.